Home LiteratureArticle Details
PMID: 16859575 Published · ppublish English Comparative Study Journal Article Review

Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.

Clinical genitourinary cancer ·Vol. 5 ·No. 1 ·2006-06-00 ·Pages 23-5

Reddy K

Abstract

暂无摘要

MeSH Terms
Antineoplastic Agents/therapeutic use Carcinoma, Renal Cell/drug therapy,secondary Clinical Trials, Phase III as Topic Humans Indoles/therapeutic use Interferon-alpha/therapeutic use Kidney Neoplasms/drug therapy,pathology Pyrroles/therapeutic use Randomized Controlled Trials as Topic Sunitinib
Chemicals
Antineoplastic Agents Indoles Interferon-alpha Pyrroles Sunitinib
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Reddy Kesava
Article Info
Journal
Clinical genitourinary cancer
Abbr.
Clin Genitourin Cancer
ISSN
1558-7673
DOI
10.1016/s1558-7673(11)70151-3
Published
2006-06-00
Pages
23-5
Language
English
Region
United States
NLM ID
101260955
Subset
IM
External Links
PubMed source DOI: 10.1016/s1558-7673(11)70151-3 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2